Sigma Healthcare Ltd SIG

Private equity owner Sycamore is reportedly in advanced talks over the sale, only a year after taking over Boots.

Foreign investors have poured a record US$942b into US equities over 12 months, which leaves plenty of global money hunting for the next pocket of value. That spotlight often shifts to Australian businesses with strong cash generation and resilient balance sheets that trade below what careful analysis suggests they are worth. This article highlights three such high quality but underpriced Australian stocks from our value-focused screener. The three stocks below are just a starting sample from...

Sigma Healthcare Ltd (SIGGF) delivers record FY26 results with normalized EBIT up over 20% and Chemist Warehouse network sales hitting $10.2 billion milestone.

The Telegraph reported that the revised approach was turned down following months of talks, leaving the possible acquisition uncertain.

Boots’ £7bn takeover by the Weston family is at risk of collapse, The Telegraph can reveal.

Sigma ends Boots discussions after deciding the deal would not meet current strategic and capital investment objectives.

Boots has been under mutliple ownerships including by Walgreen but the next owner will not be Australia's Sigma after it pulled out of talks.

Sycamore took control of Boots when it acquired Walgreens Boots Alliance for $23.7bn last year.

The Australian pharmacy group Sigma Healthcare has dropped out of talks for a potential takeover of Boots, a deal that would have valued the British retailer at an estimated $10bn (£7bn).

If you are wondering whether Sigma Healthcare at A$2.69 is offering fair value or an appealing entry point, a good starting point is to understand what the current market price is really reflecting. The stock is down 7.6% over the past week, 5.6% over the past month, 8.5% year to date and 15.5% over the past year. However, the 3 year return of 231.7% and 5 year return of about 4x show a very different longer term picture. Recent headlines around Sigma Healthcare have focused on the ongoing...

Sycamore is reportedly speaking with the Weston family and Sigma Healthcare about selling Boots.

Sigma has acknowledged its participation in the process, telling the Financial Times it had “engaged in preliminary discussions in relation to the sale process”.

Boots is in talks to sell itself for £7.5bn to the family behind Primark and an Australian pharmacy chain.

As the Australian market navigates a cautious start to the week, with modest gains and an eye on economic indicators and international developments, investors are closely monitoring potential opportunities. Penny stocks, despite their somewhat outdated moniker, remain an intriguing investment area for those seeking growth in smaller or newer companies. These stocks can offer significant value when backed by robust financials, and we'll explore three such examples that may present promising...

The Australian share market is experiencing a challenging period, with a recent downturn marking its seventh consecutive day of declines. Amidst these broader market movements, penny stocks remain an intriguing option for investors interested in companies that are smaller or less established but potentially offer significant value. While the term "penny stocks" may seem outdated, it still represents an area where investors can find opportunities by focusing on those with strong financials and...